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Abstract 
 
Unsolved riddle of cancer remains a major global health concern particularly 
in hepatocellular carcinoma (HCC) which is among the leading causes of cancer-
related death worldwide. Saffron (Crocus sativus L.) and its bioactive phytochemicals 
possess promising anti-cancer activities. One of these phytochemicals, safranal, has 
demonstrated potent anti-cancer activities against different types of cancers. Yet, its 
association with liver cancer remains under documented. This study investigated HCC 
response to safranal’s treatment via transcriptomic approach. Safranal was found to be 
involved in mitochondrial dysfunction, induced oxidative stress and increased reactive 
oxygen species (ROS) production leading to cell death. Interestingly, safranal has 
seemingly interfered with mitogen-activated protein kinase (MAPK) signaling 
pathway that is responsible for cell growth, proliferation, differentiation and survival. 
Through ingenuity pathway analysis (IPA), 45 genes were associated with HCC 
inhibition. To further pinpoint specific genes, IPA re-analysis revealed 8 genes to be 
associated with decrease in tumor’s incidence and angiogenesity. Taken together, this 
study unravel safranal’s novel potential as a natural therapeutic agent and a much 
needed adjuvant against HCC. 
 
Keywords: Hepatocellular carcinoma, RNA sequencing, Saffron, Safranal, Transcriptomic 
analysis. 
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 )cibarA ni( tcartsbA dna eltiT
 
 تحليل ترنسكربيتومي لنموذج سرطان الكبد طبقا لإستجابته لعلاج الزعفران
 صالملخ
 المشكلات الصحية على مستوىيبقى مرض السرطان، المرض العضال، أحد أبرز 
و الذي يعتبر من ضمن الأسباب الرئيسية المرتبطة بوفيات  )CCH( ا سرطان الكبدو لا سيم العالم 
 و ما يشمله من ).L suvitas sucorCالزعفران ( من خلالهذه الدراسة  تستفيدالسرطان عالميا.َ و 
المواد  تحمل خصائص مضادة لبعض الأنشطة السرطانية. إن أحد هذه مواد كيميائية نباتية
يتمتع بخصائص مضادة عالية لمختلف أنواع السرطانات وعلى الرغم من ) lanarfaS( الكيميائية
ناول لدراسة. و تتؤل و تستلزم المزيد من البحث و اذلك تبقى علاقته بسرطان الكبد محل تسا
من منظور ) lanarfaS(علاج بـ لل )CCH(  سرطان الكبد ابة الدراسة التي بين أيدينا استج
 .)cimotpicsnarT( يترانسكبتوم
 تسبب في إختلال الميتوكوندريا، و قد زاد أيضا َ من إنتاج ) lanarfaS(وجد أن الـ 
) مما جعله يصل إلى مرحلة يصبح فيها موت الخلية إلزاميا.َ و SOR( التفاعلية الأكسجين أنواع
) و هي المسؤولة عن النمو، تكاثر، KPAMأيضا بصورة مدهشة بـ ألية ( )lanarfaS(قد تتدخل 
 .تمايز الخلوي و بقاء الخلية على قيد الحياة
لإحباط  تمت بصلة  الوراثية جيناتالمن  54، ُعرف أن  )API( و عند إجراء تحليل
مما  ) للجينات السابقة، API( تحليللمزيد من الدقة تم إعادة إجراء ، ول)CCH(سرطان الكبد 
 نمومن الجينات الوراثية التي  لها علاقة بتقليل نسب حدوث السرطان و  8 إيجادساعد على 
) lanarfaS(ه الخصائص الفريدة للـ ذو بهذا، فإن هذه الدراسة تقدم هالأوعية الدموية الجديدة. 
 . )CCH(سرطان الكبدو مادة مساعدة ضد  كمنتج علاجي طبيعي
، ، الزعفرانتسلسل الحمض النووي الرايبوزيتقنية سرطان الكبد، : البحث الرئيسية مفاهيم
  .التحليل الترنسكربيتومي
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Chapter 1: Introduction 
 
1.1 Cancer 
 Cancer riddle remains unresolved and stubbornly lingers as major global health 
concern. Cancer is a disease that is characterized by uncontrolled growth and division 
of genetically unstable cells. The accumulation of genomic alterations varies among 
different subpopulations of cells and accounts for the heterogeneity of cancer (Shen, 
2011; Ferguson et al., 2015).  The terms tumor and cancer may often be used 
interchangeably, however, that is not always the case. Tumor refers to the abnormal 
growth of mass and might be either benign or malignant growth. A benign tumor is an 
abnormal growth confined to its original place and it can be removed surgically.  A 
malignant tumor is able to invade surrounding tissues and spread out to distant body 
sites by means of the circulatory or lymphatic systems hence referred as metastasis 
process. Only malignant tumors are denoted as cancer reinforcing the fact of their 
ability to metastasize (Cooper, 2000). 
 Cancer cells acquire distinct 6 biological features from their normal 
counterparts. These biological features were first introduced in 2000 and were defined 
as hallmarks of cancer consist of sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis and activating invasion and metastasis. In 2011, additional 4 hallmarks 
of cancer were introduced which were deregulating cellular energetics, avoiding 
immune destruction, genomic instability and mutation and tumor promoting 
inflammation (Hanahan and Weinberg, 2011). 
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 Cancer is the second leading cause of death worldwide accounting for 8.8 
million deaths in 2015; that is 1 in every 6 deaths is due to cancer (World Health 
Organization, 2018). Top cancer mortality were attributed to lung cancer by 1.69 
million deaths, liver cancer by 788000 deaths, colorectal cancer by 774000 deaths, 
stomach cancer by 754000 deaths and breast cancer by 571000 deaths. It is estimated 
that in the next two decades, the number of new cases of cancer could mark a 70% 
increase revealing an overwhelming cancer expansion. 
 According to Authority of Health of United Arab Emirates in Abu Dhabi, 
cancer is the third leading cause of death accounting for total 16% deaths that comes 
after road trauma injuries and cardiovascular diseases (Health Authority of Abu Dhabi, 
2018). Records of around 427 death cases were documented due to cancer in 2015 with 
56% male and 44% female. Top cancer mortality were attributed to lung cancer, 
colorectal cancer, liver cancer, leukaemia and pancreas cancer in men. 
 There are almost 200 types of cancer, their classification depends on the site of 
origin or the cell type originated from. Cancer is mostly classified into three large 
groups. Carcinomas are malignancies of epithelial cells and are considered the most 
common of human cancers such as squamous cell carcinoma, adenocarcinoma, 
melanoma and basal cell carcinoma. Sarcomas are solid tumors of connective tissues, 
such as muscle, bone, cartilage, and fibrous tissue and are considered rare in humans. 
Lastly, leukemias and lymphomas are malignancies rose from the blood cells and 
immune system cells, respectively (Cooper, 2000; Kirkham and Shepherd, 2001; Song 
et al., 2015).   
3 
 
 
 
 
1.1.1 Liver cancer  
 Liver is one of the vital organs that might become susceptible to cancer 
development. Liver importance rise from its wide range of functions such as 
metabolism, digestion, and detoxification. It is the only known human internal organ 
that is capable of regeneration (Laursen, 2014). Liver cancer is found to be fairly 
problematic to treat, and quite lethal in case of late diagnosis. In fact, thanks to its poor 
diagnosis, liver cancer is now the second leading cause of global cancer-related death 
with more prevalence in males rather than females (Torre et al., 2015). Primary liver 
cancer can normally be distinguished into several different forms of cancer including 
hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA); also known as Bile-
duct cancer, and hepatoblastoma. HCC is the most common primary liver cancer by 
approximant 78% of incidence. CCA accounts for 15% of incidence while 
hepatoblastoma and other various liver sarcomas and carcinomas accounts for 7% of 
incidence (Laursen, 2014).  
1.1.2 Hepatocellular carcinoma  
 Due to the wide prevalence of HCC over all other forms of liver cancer, its 
aggressiveness, high rate malignancy and poor prognosis, HCC is the main contributor 
to the global health burden of liver cancer (Tanaka and Arii, 2012). HCC originate 
from adult hepatocytes upon genomic insult thereby dedifferentiate into precursor cells 
that eventually transform into HCC cells (Sia et al., 2017). HCC is rather strongly 
associated with numerous risk factors, including cirrhosis, chronic hepatitis B virus 
(HBV), chronic hepatitis C virus (HCV), hepatitis D virus (HDV)  infections, alcohol 
abuse, nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis 
(NASH) (Ghouri et al., 2017).  
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 Although the overall incidence of HCC varies based on etiology, ethnicity, 
gender, age, and geographic region, still that does not overpower the most common 
existence of fibrosis in HCC (Zhang and Friedman, 2012). In fact, around 90% of HCC 
occurrence take place under cirrhosis settings (Seitz and Stickel, 2006). Hepatotropic 
viruses, HBV, HCV and HDV, and their association with HCC development explains 
the higher rate of HCC in certain geographical region. For instance, 10-20% of Eastern 
Asia and Central Africa population are infected with HBV, the incidence of HCC is 
30-120 in every 100,000 residents while in North and South America, and Europe, 
where less HBV infections exist, the incidence of HCC is only 5-10 in every 100,000 
residents (Simon et al., 2012). There is a close relationship almost synergistic between 
the hepatotropic viruses; namely HBV and HCV infections, and alcohol intake to 
increase the possibility of HCC development. Yet, even without HBV or HCV 
infections, the effects of alcohol intake on HCC development was evident (Donato et 
al., 2002). NAFLD is chronic liver disease with wide spectrum stretching from simple 
hepatic steatosis to a more serious liver injury and inflammation recognized as NASH 
(Cholankeril et al., 2017). In reality, 15-20% of patients of NAFLD have developed 
NASH (Zezos and Renner, 2014). Exponential increase of HCC development due to 
NASH risk factor is highly anticipated as the prevalence of NASH is expected to 
escalate thanks to the growing epidemic of obesity and diabetes (Cholankeril et al., 
2017). 
1.1.3 Hepatocellular carcinoma diagnoses 
 In general, early diagnoses dramatically enhance the survival rate of cancer 
patients as the tumor mass is still restrained within the organ of origin (Kakushadze et 
al, 2017). This is ineligible to HCC as the lack of clear symptoms and coexistence of 
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HCC with other related diseases often hinders the process of distinguishing and 
detecting HCC. Only 25% of the total HCC patients were diagnosed within early stage 
of HCC, that is when a single node of HCC is smaller than 5 cm, or three nodes of 
HCC each smaller than 3 cm (Farinati et al., 2009; Tsuchiya et al., 2015). It is often 
recommended for patients with liver cirrhosis or chronic liver diseases to have regular 
screening tests to take advantage of early HCC diagnosis. Yet, gaining the benefit of 
early HCC diagnosis is only possible if the liver function is still compensated. Sadly, 
this does not work in patients having impaired liver function (Plentz and Malek, 2015).  
1.1.4 Hepatocellular carcinoma treatment  
 Several factors should be taken into consideration when HCC therapeutic 
strategies in question. These factors are tumor size and location, extrahepatic spread, 
HCC stage, patient’s performance status and underlying liver function (Crissien and 
Frenette, 2014).  The standard curative treatments of HCC is represented by either 
surgical resection or liver transplantation. Yet, those surgical managements are only 
applicable for early stage HCC achieving 5 years’ survival with approximate of 50% 
overall survival rates (Pang and Lam, 2014). Intermediate stage HCC might be eligible 
for resection therapy as their only option for curative treatment. Other therapeutic 
options can be locoregional therapy including percutaneous ethanol injection (PEI), 
trans-arterial chemoembolization (TACE) and radiofrequency ablation (RFA). 
Sorafenib is the first line treatment of advanced stage HCC which is also considered 
as palliative treatment. Whilst, terminal stage HCC receives symptomatic treatment as 
the only possible approach out there (Bruix and Sherman, 2011; Raza and Sood, 2014).  
 In advanced stage HCC, sorafenib (Nexavar) was the only chemotherapeutic 
regimen approved by Food and Drug Administration (FDA). Most recently 
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regorafenib (Stivarga) was another chemotherapeutic FDA approved as second line 
treatment to be administrated to patients who have been previously treated with 
sorafenib (Rimassa et al., 2017; Ziogas and Tsoulfas, 2017). Regorafenib is 
structurally similar to Sorafenib but with different biochemical profile (Mirantes et al., 
2016). Sorafenib mechanism of action is expressed through its ability to inhibit 
multiple molecular targets mainly kinases involved in tumor proliferation and 
angiogenesis. These targets are serine-threonine kinases CRAF and BRAF involved in 
RAF/MEK/ERK signaling cascade, RET, FLT-3, tyrosine kinase activity of vascular 
endothelial growth factor receptors (VEGFRs) 1, 2 and 3 and platelet-derived growth 
factor receptor β (PDGFR-β) (Le Grazie et al., 2017). Despite the positive effect of 
sorafenib on advance stage HCC patients, the average overall survival is only 
prolonged by nearly 3 months (Llovet et al., 2008).  Moreover, sorafenib exhibited 
some adverse effects such as skin-related toxicities, hypertension, proteinuria, 
diarrhea, and cytopenias. Other serious life-threatening complications have been 
witnessed as well including thromboembolism, bleeding, and bowel perforation. This 
has led 20-30% of patients to discontinue sorafenib’s use (Crissien and Frenette, 2014). 
In addition, the initial responses might seems promising but over time loss of efficacy 
become evident which most probably due to drug resistance. Hence, new treatments 
of HCC are desperately needed. 
1.2 Herbal medicine  
       Form the ancient times and throughout mankind civilization, herbal/traditional 
medicine was used on a regular basis to cure human diseases. Gradually but steadily, 
modern medical practices replaced herbal medicine although the later still holds a solid 
ground in many parts of the world especially the developing countries largely due to 
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its cultural acceptance and less adverse effects (Rana and Rana, 2014). The therapeutic 
value of a specific herb can be gained from the biologically active extracts or from the 
intact plant which display drug-like properties. Thus different methodologies of 
extraction, molecular characterization, standardization and some possible slight 
modification on the biological active components could enhance the drug-like activity. 
Within the last decade, improving extraction methods promoted herbal medicine 
among the scientific communities (Ansari et al., 2012). As matter of fact, 25% of 
worldwide drugs are actually derived from plants and 121 biological active extract are 
in use (Rates, 2001).  
1.2.1 Saffron 
 Saffron is the dried stigma of the plant Crocus sativus L.; a member of 
Iridaceae family. The flower of C. sativa is light purple with three thread-like reddish-
colored stigmas that are recognized as saffron spice and as a natural colorant. Saffron 
is known as “red gold” in the producing countries such as Iran, India and Greece. It 
has uphold its reputation as the most expensive cultivated spice herb in the world due 
to cultivation labor, harvesting, and handling since it has to be handpicked. About 
70,000 flowers are needed obtain over 200000 dried stigmas to yield enough for 500 
g pure saffron (Srivastava et al., 2010; Gohari et al., 2013; Hosseinzadeh, 2014).  
 Saffron has been traditionally used to treat cramps, asthma and bronchospasms, 
menstruation disorders, liver disease and pain. It was claimed to have a soothing and 
tonifying effect on the gastrointestinal tract. Also it has been used as stimulant and 
antidepressant (Schmidt et al., 2007). Recently, other medical properties have been 
associated with saffron including anti-tumor effects, anti-inflammatory effects and 
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cardioprotective effect (Abdullaev, 2002; Mehdizadeh et al., 2013; Amin and 
Hosseinzadeh, 2015). 
 Around 150 volatile and non-volatile compounds are present in saffron, 
however, less than 50 constituents have been identified. Among the volatiles, the main 
component is safranal whilst the non-volatile component are crocins, crocetin, 
picrocrocin and flavonoids (quercetin and kaempferol). Crocin structurally is glucosyl 
esters of crocetin and is found to be water-soluble carotenoids that is responsible for 
saffron’s characteristic red color. Picrocrocin is structurally glycoside of safranal and 
is responsible for the bitter taste of the spice. Safranal is the main component of the 
distilled essential oil and is a monoterpene aldehyde that is responsible for saffron’s 
characteristic aroma. Safranal, crocin and crocetin are considered to be the main 
constituents of saffron and are heavily investigated for their biological activates 
(Pitsikas, 2016).  
1.2.2 Safranal  
 Amongst its biological activities, safranal was found to exert potent 
anticonvulsant activity (Hosseinzadeh and Sadeghnia, 2007), anti-oxidant activities 
(Hosseinzadeh et al., 2005; Hosseinzadeh and Sadeghnia, 2005; Hosseinzadeh et al., 
2009), anti-inflammatory activities (Hazman and Bozkurt, 2015) and anti-tumor 
activities (Shabestari and Samarghandian, 2013; Farahzad et al., 2014; Zhang et al., 
2017). The molecular basis of safranal’s profound anti-cancer effects remains unclear. 
1.3 Transcriptome profiling  
 Transcriptome is the complete set of RNA transcripts and their quantity in a 
given cell under certain developmental stage or physiological condition. Investigating 
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the transcriptome may explain the functional elements of the genome and the 
underlying mechanisms of development or disease (Wang et al., 2009; Yang and Kim, 
2015). Transcriptome started in 1991 with a partial human transcriptome covering a 
mere of 609 mRNA sequences. In 2008, two human transcriptomes consisting of 
millions of transcript covering 16,000 genes. Transcriptomes of hundreds of 
individuals can now be analyzed just like any other routine laboratory procedure. This 
cascade of transcriptomes evolution clearly reflects the drastic development of new 
transcriptome technologies (Lowe et al., 2017). 
 Gene expression studies at first were conducted using northern blots and 
quantitative polymerase chain reaction (qPCR) both considered as low-throughput 
methods allowing few number of transcripts measurement. Then, a sequence-based 
technology was developed where generated expressed sequence tag (EST) libraries by 
Sanger sequencing of complementary DNA (cDNA) was used in gene expression 
studies, yet transcript quantification was not practical. Several tag-based methods were 
also developed to yield a higher throughput and precise quantification of expression 
levels such as serial analysis of gene expression (SAGE) and cap analysis gene 
expression (CAGE). For high-throughput method, hybridization-based microarray 
technologies could be performed but with notable limitations. For instance, 
priori sequence information is required and cross-hybridization artifacts may interfere 
with the correct interpretation. Methodologies described here are insensitive toward 
splice isoforms and are not set to identify novel genes (Shendure, 2008; Kukurba and 
Montgomery, 2015; Hrdlickova et al., 2016).  
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1.3.1 RNA sequencing  
 RNA sequencing (RNA-seq) is high-throughput sequencing method. Unlike, 
Sanger sequencing and microarray-based methods, RNA-Seq provides better coverage 
and superior overview of transcriptomic dynamic nature. Not only gene expression 
quantification is generated but also novel transcripts are discovered, alternatively 
spliced genes are identified and allele-specific expression are detected. (Kukurba and 
Montgomery, 2015).  
 RNA-seq standard workflow is shown in (Fig. 1). It starts with the 
experimental set-up where the purpose of the study is outlined and statistical design is 
taken into consideration. Tissue preparation and library generation, herein, involve 
samples collection, RNA extraction and quality assessment, rRNA depletion or poly-
A enrichment, cDNA synthesis, library preparation, polymerase chain reaction (PCR) 
reaction and library normalization. Then comes the high-throughput sequencing where 
the sequencing platform is chosen, sequence coverage is decided. Then comes the 
bioinformatics processing part, where critical needs should be met such as computing 
resources and programing skills to aid in transcriptome reconstruction, mapping 
strategy, gene expression quantification. Afterword, the biological inference involves 
normalization, differential gene expression, gene function and interaction. Lastly, 
experimental validation is needed where quantitative polymerase chain reaction 
(qPCR) quantification becomes handy. 
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Figure 1: A standard RNA-seq workflow (adapted from Wolf, 2013) 
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1.4 Hypothesis to be tasted  
 The hypothesis of this study is considering saffron’s reputation as potent anti-
cancer natural based product, will safranal holdup the same anti-cancer effect against 
HCC? And what are some of its underlying mechanism? 
1.5 Aims of the study 
 The overall aim of this study is to investigate safranal’s therapeutic effect on 
HCC through transcriptomic approach.  
The specific objectives are: 
1. Transcriptomic analysis to figure out significant candidate genes involved in 
HCC due to safranal treatment. 
2. Verification of the result obtained from RNA seq using qPCR quantification. 
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Chapter 2: Methods 
 
2.1 In vivo Study  
2.1.1 Animal 
 Wister male rats were obtained from the animal facility of the College of 
Medicine and Health Sciences, UAEU. Animals were housed under a 12 hr light/dark 
cycle at 24 – 26°C.  They were maintained on standard laboratory animal diet with 
food and water ad libitum. All animal studies were carried out in accordance with, and 
after approval of the Animal Research Ethics Committee of the College of Medicine 
and Health Sciences, UAEU (Approval No. A8-15). 
2.1.2 Experimental design  
 The experimental protocol of HCC development was adapted and followed in 
our lab as per described by DePeralta et al. (2016) and Pacheco-Rivera et al. (2016) 
with some modifications and adjustments. This study was performed with an average 
weighing 170 g male Wistar rats. Wistar rats were randomly divided into 8 groups 
(n=6). The first 4 groups were labelled as control groups subdivided into control water 
(C W), control safranal (C SF), control sorafenib (C SB) and control safranal and 
sorafenib (C SF SB). Whereas the remaining 4 groups labelled as experimental groups 
subdivided into HCC (H), HCC treated with safranal (H SF), HCC treated with 
sorafenib (H SB) and HCC treated with both safranal and sorafenib (H SF SB).       
 Control groups were subjected to the following treatments: Group 1 (C W): Rats were 
treated with distilled water alone throughout the experimental period. Group 2 (C SF): Rats 
were administered orally 200 mg/kg of safranal 5 days a week for 3 weeks, total of 15 oral 
gavage doses. This dose was selected based on a preventive study of safranal on nephrotoxicity 
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(Karafakıoğlu et al., 2017). Group 3 (C SB): Rats were administered orally 10 mg/kg of 
sorafenib 5 days a week for 3 weeks, total of 15 oral gavage doses. This dose was selected 
based on earlier studies of sorafenib on a rat HCC model (Alsaied et al., 2014; Wang et al., 
2014; El-Ashmawy et al., 2016). Group 4 (C SF SB): Rats were administered orally both doses 
of 200 mg/kg of safranal and 10 mg/kg of sorafenib 5 days a week for 3 weeks, total of 15 oral 
gavage doses.   
Whereas the experimental groups were subjected to the following treatments: 
Group 5 (H): Rats were injected intraperitoneally with 50 mg/kg of diethylnitrosamine 
(DEN) once a week for 15 week, total of 15 injections. Group 6 (H SF): Rats were 
injected intraperitoneally with 50 mg/kg of DEN once a week for 15 week, total of 15 
injections and then followed by orally administered 200 mg/kg of safranal 5 days a 
week for 3 weeks, total of 15 oral gavage doses. Group 7 (H SB): Rats were injected 
intraperitoneally with 50 mg/kg of DEN once a week for 15 week, total of 15 injections 
and then followed by orally administered 10 mg/kg of sorafenib 5 days a week for 3 
weeks, total of 15 oral gavage doses. Group 8 (H SF SB): Rats were injected 
intraperitoneally with 50 mg/kg of DEN once a week for 15 week, total of 15 injections 
and then followed by orally administered both doses of 200 mg/kg of  safranal and 10 
mg/kg of sorafenib 5 days a week for 3 weeks, total of 15 oral gavage doses.   
 At the  end  of  experimental  period and 24  hrs after  the last treatment, rats  
were anesthetized  by  mild  Diethyl  ether  and  dissected (Fig. 2). The whole liver 
was removed and immediately flash frozen for further analysis. This experimental 
model has been developed and HCC development has been histopathologically 
confirmed and well characterized in our lab (AlMansoori ongoing MSc Thesis).  
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2.2 Transcriptomic analysis  
2.2.1 RNA extraction  
Total RNA was extracted from flash frozen liver tissues using Maxwell 16 
System along with Maxwell 16 Total RNA Purification Kit (Promega, US), according 
to the manufacturer’s instructions with slight modifications. Briefly, 50 mg of liver 
tissue immersed in 200 µl lysis buffer with 2 µl of β-mercaptoethanol (BME) was 
mechanically homogenized until no visible tissue fragments is seen. The homogenized 
sample was incubated for 10 min on ice for a complete lysis. Microcentrifuge was used 
for a quick spin and the sample lysate was transferred into a new 1.5 ml 
microcentrifuge tube. 167 µl of RNA dilution buffer was added to the sample lysate 
along with 125 µl of a completely resuspend the clearing agent. The sample was 
vortexed for 30 sec then it was placed in 70°C heat block for 3 min. After heating the 
Figure 2: Schematic illustration of the in vivo experimental design (adapted from 
AlMansoori ongoing MSc Thesis) 
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sample was vortexed again for 30 sec and incubated for 5 min at room temperature. 
After that the sample was transferred into clearing column assembly and centrifuged 
at 12,000 × g for 2 min.  
Afterward, the collected flowthrough from the collection tube was transferred 
into first wall of maxwell 16 RNA cartridge while a plunger was placed into the last 
wall of the cartridge. A 200 µl of nuclease-free water was placed in a separate elution 
tube. Maxwell 16 Instrument was programmed according to the manufacturer’s 
instructions. Upon the completion of the RNA purification, the elution tube was 
removed from the platform and placed into magnetic elution tube rack for 10 min. the 
eluted sample of total RNA was then transferred into a storage tube. Total RNA 
concentration was measured using NanoDrop1000 spectrophotometer (Thermo Fisher 
Scientific Inc.) while RNA quality, RNA integrity number (RIN) was verified using 
Bioanalyzer 2100 and  RNA 6000 Nano chips according to the manufacturer’s 
instructions (Agilent Technologies, CA). Total RNA concentration and RIN value per 
sample are listed in (Table 1). 
 
Table 1: Extracted total RNA measurement 
Sample code Conc. ng/µl RIN Sample code Conc. ng/µl RIN 
G1 (C W) - 1 192.1 9.3 G5 (H) - 1 306.6 N/A* 
G1 (C W) - 2 121.8 9.4 G5 (H) - 2 435.1 8.6 
G1 (C W) - 3 191.9 9.5 G5 (H) - 3 199 9.1 
G2 (C SF) - 1 242.8 9.3 G6 (H SF) - 1 530.4 9.0 
G2 (C SF) - 2 165.1 9.1 G6 (H SF) - 2 328.4 9.3 
G2 (C SF) - 3 258.8 9.1 G6 (H SF) - 3 296.3 9.2 
G3 (C SB) - 1 259.4 9.1 G7 (H SB) - 1 139.6 9.2 
G3 (C SB) - 2 226.9 8.9 G7 (H SB) - 2 204.9 9.0 
G3 (C SB) - 3 265.6 9.4 G7 (H SB) - 3 190.1 9.6 
G4 (C SF SB) - 1 211.7 9.1 G8 (H SF SB) - 1 209.7 9.2 
G4 (C SF SB) - 2 233.4 8.9 G8 (H SF SB) - 2 255.9 9.1 
G4 (C SF SB) - 3 205.8 9.0 G8 (H SF SB) - 3 223.3 9.2 
Note: (*) not available due to disturbance in the fast region estimated to be 9.2. 
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2.2.2 RNA-seq libraries construction, sequencing and analysis 
 Brigham Young University DNA Sequencing Center (Provo, Utah, USA) 
provided the service of library preparation and sequencing. Briefly, RNA-seq libraries 
were prepared using KAPA Stranded mRNA-Seq kit Illumina Platforms (KAPA 
Biosystems, US) following the manufacturer’s instructions. The kit is based on poly-
A mRNA enrichment. The produced libraries were quantified using a Kapa library 
quantification kit Illumina Platforms (KAPA Biosystems, US) based on SYBR green 
chemistry. Libraries were sequenced on an Illumina HiSeq 2500 sequencing system 
(Illumina, Inc.) to a minimum of 20 million reads per sample.   
 Bioinformatics Core at New York University Abu Dhabi (NYUAB) have 
processed the generated data through their standard RNA-seq analysis pipeline.  In 
short, alignments were performed using tophat2 v2.1.0 (Kim et al., 2013). Following 
the tophat2 alignment stage, read counts were generated using HTseq count (Anders 
et al., 2014).  
2.2.3 Hierarchical cluster and principle component analyses 
 Both hierarchical cluster analysis principle component analysis (PCA) were 
constructed by uploading the raw count into ClustVis, web tool for visualizing 
clustering of multivariate data (Metsalu and Vilo, 2015). 
2.2.4 Differential gene expression analysis  
To generate differential expressed genes (DEGs) and their volcano plots, raw 
counts were analyzed using RNA-seq 2G (http://52.90.192.24:3838/rnaseq2g/) an 
online interface, user friendly, with over 25 statistical methods used to perform two-
group analysis of differential gene expression. DESeq2 statistical method was 
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employed and significant genes were identified using cutoff values of false discovery 
rate (FDR) < 0.05, and log 2 (fold change).Venn diagrams were constructed using 
InteractiVenn, web-based tool (Heberle et al., 2015). Gene expected function was 
extracted using Rat Genomic Database (RGD) (Shimoyama et al., 2015). 
2.2.5 Gene ontology enrichment analysis 
 Gene set enrichment analysis of DEGs was performed using the Biological 
Networks Gene Ontology tool (BiNGO) (Maere et al., 2005), plug-in for Cytoscape 
software (Shannon et al., 2003).  BiNGO found the relevant biological process 
annotations. This enrichment test is based on hypergeometric test and corrected 
multiple testing using Benjamini and Hochberg FDR correction ≤ 0.05. 
2.2.6 Pathway analysis 
 DEGs were analyzed through Ingenuity Pathway Analysis (IPA) (QIAGEN 
Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) 
(Krämer et al., 2014). To allow more stringent analysis, the cutoff value of FDR was 
set to 0.01. Core analysis were implicated with default settings, canonical pathways 
and associated toxicity functions were reviewed. 45 genes that were associated with 
HCC were re-analyzed (core analysis) for further toxicity function association.  
 
2.2.7 Network analysis 
Network analysis were performed using Search Tool for The Retrieval of 
Interacting Genes (STRING) version 10.5 (http://string-db.org/) (Szklarczyk et al., 
2017). STRING, an online genes/proteins association database curated from literature, 
high-throughput experimental data, and predicted associations from systemic genome 
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comparisons. Rattus norvegicus databases were utilized to generate association 
network for two sets of genes of interest that showed significant fold change in 
expression.  
2.2.8 qPCR quantification   
 Previously extracted RNA was used for cDNA synthesis corresponding to 
1000 ng of total RNA using GoScript™ Reverse Transcription System (Promega US) 
according to manufacturer’s instructions. Quantitative PCR reactions were performed 
on an QuantStudio 5 Real-Time PCR System (Thermo scientific,US) using 
GoTaq® qPCR Master Mix  kit (Promega US) with gene-specific primers  as per 
manufacturer's protocol . Data were normalized relative to 18S rRNA gene values, 
which exhibited stable expression levels between the two groups of G5 (H) and G6 (H 
SF) unlike ACTB and GAPDH. Relative expression level of each gene was calculated 
using 2-ΔΔCt method. All reactions were run in triplicate. The primers for the qPCR 
reactions are listed in (Table 2).  
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Table 2: qPCR primers sequences 
Gene Forward primer (5'→3') Reverse primer (5'→3') Source  
BTG1 
CGTTGTATTCGCATCAAC
C 
AGCCATCCTCTCCAATC
C 
Li et al., 2009 
PAWR 
GCAGGACAGAAGGAACG
GAA 
TGGGGCACTGATTGTG
CTTT 
NCBI-Primer 
designing tool  (Ye 
et al., 2012) 
BMP4 
GGGATCTTTACCGGCTCC
AG 
TCTCCAGATGTTCTTCG
TGATGG 
NCBI-Primer 
designing tool  (Ye 
et al., 2012) 
DNAJB9 
GGGCGCACGGGTTATTAG
A 
CTCTGAGGCTGACTTTG
GCA 
NCBI-Primer 
designing tool  (Ye 
et al., 2012) 
CIDEA 
TCCTCGGCTGTCTCAATG
TC 
GAACCGCAGCAGACTC
CTTA 
NCBI-Primer 
designing tool  (Ye 
et al., 2012) 
18s 
RRNA 
GCAATTATTCCCCATGAA
CG 
GGCCTCACTAAACCAT
CCAA 
Asanoma et al., 
2011 
GAPDH 
AGACAGCCGCATCTTCTT
GT 
CTTGCCGTGGGTAGAG
TCAT 
Li et al., 2015 
ACTB 
AGACCTTCAACACCCCAG
C 
GTCACGCACGATTTCCC
T 
Wang et al., 2014 
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Chapter 3: Results 
 
3.1 Overview of gene expression profiles 
Out of whole data set of 32884 sequenced genes, randomly 2400 genes were 
selected to view an overall expression pattern among the different groups through 
hierarchical cluster analysis (Fig. 3). This analysis displayed visibly distinguishable 
patterns across the groups as it separated the experimental groups from the control 
groups with a twist. Cancer induced groups/experimental groups clustered together 
except for one; G5 (H) is clustered among G7 (H SB) and G8 (H SF SB) whereas G6 
(H SF) is closely clustered with control groups G1 (C W) and then G3 (C SB). And 
the rest of control groups are clustered together; G2 (C SF) and G (C SF SB).  It might 
be obvious that the experimental cluster together but based on this analysis, G6 (H SF) 
is shown gene expression pattern closer to the control groups.  
3.2 Principle component analysis  
Principle component analysis (PCA) is another methodology used for 
dimension reduction, simplifying data into 2 dimensional (2D) plot where PCA axes 
emphasize data variation. The whole data set of 32884 sequenced genes was used in 
this analysis (Fig. 4). Although a defined variance mostly on PC1 is shown among the 
different control groups still does not overweight the variance shown between the 
experimental groups. Clearly, G5 (H) is separated from the rest of the experimental 
groups. Interestingly, both G7 (H SB) and G8 (H SF SB) are located closely to each 
other also they fall within the prediction ellipse of the control groups. Whereas G6 (H 
SF) showed no variance on PC1 compared to the nearest control groups while a small 
variance could be seen on PC2 implying an overall small variance.   
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Figure 3: Heatmap of gene expression profiles for all the groups. Hierarchical cluster 
analysis represents the mean of the triplicate for each group. Raw were centered and 
unit variance scaling was applied. Groups were clustered by maximum distance and 
complete linkage. Expression levels are coloured red for high expression and grey for 
low expression. 
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Figure 4: Principle component analysis (2D) plot. Each mark represents the mean of 
the triplicate for each group. Pareto scaling were applied to rows and SVD with 
imputation was used to calculate principal components. PC1 and PC2 explain 59% and 
16.7% of the total variance, respectively along with 95% of prediction ellipses. 
 
3.3 Differential gene expression analysis  
Differentially expressed genes (DEGs) were obtained for the following 
experimental groups, G6 (H SF), G7 (H SB) and G8 (H SF SB). To define DEGs, a 
threshold was set on two categories, 0.05 false discovery rate (FDR), which was 
calculated based on p value using the Benjamini-Hochberg method and log 2 (fold 
change). Firstly, a total of 830 genes were differentially expressed in G6 (H SF) where 
484 genes were up regulated and 346 genes were down regulated. Secondly, a total of 
733 genes were differentially expressed in G7 (H SB) where 486 genes were up 
regulated and 247 genes were down regulated. Lastly, a total of 401 genes were 
differentially expressed in G8 (H SF SB) where 285 genes were up regulated and 116 
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genes were down regulated. A volcano plot is used as visualization for the fold change 
compared to the usual statistical significance of p values for each of the three 
experimental groups instead of FDR (Fig. 5A-C). Top 5 up regulated and down 
regulated DEGs of these groups are shown in (Table 3) and (Table 4), respectively. 
DEGs were found to be uniquely expressed within each respective group as well as 
other common genes were found overlapping between the three experimental groups. 
DEGs with total of 138 genes were up regulated between the three experimental groups 
while total of 47 genes were down regulated (Fig. 5D-E).  
 
 
Figure 5: Differential gene expression analysis. (A-C) Volcano plot for DEGs for 
each of the three experimental groups (A) G6 (H SF). (B) G7 (H SB). (C) G8 (H SF 
SB). Illustrating log2 (fold change) against statistical significance of –log10 (p 
values). (D-E) Venn diagrams of DEGs of the three experimental groups. (D) 
Distribution of the up regulated DEGs. (E) Distribution of the down regulated 
DEGs. 
25 
 
 
 
 
Table 3: Top up regulated DEGs in the three experimental groups 
 
  
 
 
 
Gene ID Description 
Fold 
change 
FDR Expected Function 
G6 (H SF) 
Cyp2b2 
Cytochrome P450, family 2, 
subfamily b, polypeptide 2 
12.80434 3.59E-30 
Aging; drug metabolic 
process; nicotine metabolic 
process 
Cyp2b1 
Cytochrome P450, family 2, 
subfamily b, polypeptide 1 
12.10023 1.80E-31 
Drug metabolic process; 
response to calcium ion; 
response to drug 
Ces2a Carboxylesterase 2A 6.758936 2.96E-22 Retinoid metabolic process 
Vnn1 Vanin 1 5.862473 3.18E-06 
Acute inflammatory response 
; cell-cell adhesion; chronic 
inflammatory response 
Acaa2 Acetyl-coa acyltransferase 2 5.01974 2.33E-11 
Acetyl-coa metabolic process; 
fatty acid beta-oxidation; 
cellular response to hypoxia 
G7 (H SB) 
Cpa1 Carboxypeptidase A1 9.202453 3.68E-11 Proteolysis 
Aldh3a1 
Aldehyde dehydrogenase 3 
family, member A1 
8.399899 9.81E-19 
Aging; positive regulation of 
cell proliferation; response to 
camp 
Akr1b8 
Aldo-keto reductase family 
1, member B8 
6.098191 3.06E-12 Oxidation-reduction process 
Nefl 
Neurofilament, light 
polypeptide 
5.641934 3.37E-06 
Cerebral cortex development; 
hippocampus development; 
intermediate filament 
polymerization or 
depolymerization 
Slc10a4 
Solute carrier family 10, 
member 4 4.828877 0.000127 
Adult behavior; response to 
drug  
G8 (H SF SB) 
Cyp2b1 
Cytochrome P450, family 2, 
subfamily b, polypeptide 1 
11.55794 9.21E-30 
Drug metabolic process; 
response to calcium ion; 
response to drug 
Cyp2b2 
Cytochrome P450, family 2, 
subfamily b, polypeptide 2 
10.36073 9.21E-30 
Aging; drug metabolic 
process; nicotine metabolic 
process 
Akr1b8 
Aldo-keto reductase family 
1, member B8 
4.650745 1.61E-18 Oxidation-reduction process 
Cpa1 Carboxypeptidase A1 4.281811 0.000209 Proteolysis 
Acaa2 Acetyl-coa acyltransferase 2 3.832358 1.51E-08 
Acetyl-coa metabolic process; 
fatty acid beta-oxidation; 
cellular response to hypoxia 
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Table 4: Top down regulated DEGs in the three experimental groups 
Gene ID Description 
Fold 
change 
FDR Expected Function 
G6 (H SF) 
Arntl2 
Aryl hydrocarbon 
receptor nuclear 
translocator-like 2 
-4.64973 0.000397 
Circadian rhythm; positive 
regulation of circadian rhythm; 
positive regulation of transcription 
by RNA polymerase II 
LOC102549948 
Uncharacterized 
LOC102549948 
-4.34139 0.002859 Unkown 
Hcn3 
Hyperpolarization-
activated cyclic 
nucleotide-gated 
potassium channel 3 
-4.32149 0.001026 
Cellular response to dopamine; 
response to cisplatin; potassium 
ion transmembrane transport 
Npas2 
Neuronal PAS 
domain protein 2 
-4.2387 7.08E-07 
Circadian regulation of gene 
expression; circadian rhythm; 
ND2 
NADH 
dehydrogenase 
subunit 2 
-4.20382 3.88E-05 
Reactive oxygen species 
metabolic process 
G7 (H SB) 
Ptx3 Pentraxin 3 -6.06793 6.68E-10 
Negative regulation by host of 
viral exo-alpha-sialidase activity; 
negative regulation by host of 
viral glycoprotein metabolic 
process 
Fos 
FBJ osteosarcoma 
oncogene 
-4.86634 1.24E-10 
Aging; cellular response to 
hormone stimulus; conditioned 
taste aversion 
Pcdh17 Protocadherin 17 -4.71013 1.53E-06 
Adult behavior; negative 
regulation of synaptic 
transmission; presynaptic active 
zone assembly 
Opcml 
Opioid binding 
protein/cell adhesion 
molecule-like 
-4.36873 0.000109 Cell adhesion 
Lrrtm2 
Leucine rich repeat 
transmembrane 
neuronal 2 
-4.02803 6.18E-05 
Synapse organization; long-term 
synaptic potentiation; negative 
regulation of receptor 
internalization; 
G8 (H SF SB) 
Fos 
FBJ osteosarcoma 
oncogene 
-5.8923 1.68E-12 
Aging; cellular response to 
hormone stimulus; conditioned 
taste aversion 
Ptx3 Pentraxin 3 -3.80319 6.69E-06 
Negative regulation by host of 
viral exo-alpha-sialidase activity; 
negative regulation by host of 
viral glycoprotein metabolic 
process 
Inhba 
Inhibin beta A 
subunit 
-3.73907 4.18E-08 
Cellular response to cholesterol; 
cellular response to follicle-
stimulating hormone stimulus; 
activin receptor signaling pathway 
Ngp 
Neutrophilic granule 
protein 
-3.59586 0.001207 
Defense response; negative 
regulation of endopeptidase 
activity 
Tlr12 Toll-like receptor 12 -3.46918 5.02E-05 Signal transduction 
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3.4 Gene ontology enrichment analysis  
In order to investigate the biological processes associated with DEGs, gene 
ontology (GO) enrichment analysis was performed using BiNGO, a known Cytoscape 
software plugin. This analysis was carried out on the up regulated and the down 
regulated genes for the three experimental groups G6 (H SF), G7 (H SB) and G8 (H 
SF SB) in addition to the up regulated and the down regulated common genes 
mentioned previously (Table 5). 
 
Table 5: List of relevant GO enrichment analysis 
 
Term name 
Genes 
number 
FDR Term name 
Genes 
number 
FDR 
G6 (H SF) Up regulated G6 (H SF) Down regulated 
Regulation of 
programmed cell death 
36 2.85E-03 Cellular respiration 8 2.14E-03 
Response to organic 
substance 
80 9.15E-14 
Regulation of 
biological process 
89 2.40E-02 
Response to stress 71 9.63E-06 
Negative regulation of 
biosynthetic process 
17 2.59E-02 
G7 (H SB) Up regulated G7 (H SB) Down regulated 
Response to drug 26 7.92E-04 Electron transport chain 6 2.30E-02 
Response to oxidative 
stress 
19 1.15E-04 Cellular respiration 5 3.83E-02 
Regulation of cell 
projection size 
2 3.82E-02 
Negative regulation of 
cellular process 
29 3.72E-02 
G8 (H SF SB) Up regulated G8 (H SF SB) Down regulated 
Response to drug 25 4.32E-07 
Regulation of 
epinephrine secretion 
2 1.96E-02 
Regulation of lipid 
metabolic process 
11 1.41E-04 
Cyclooxygenase 
pathway 
2 1.66E-02 
Regulation of tumor 
necrosis factor 
production 
4 1.33E-02 
Regulation of 
macrophage 
differentiation 
2 3.70E-02 
Common genes - Up regulated Common genes - Down regulated 
Response to drug 12 2.73E-03 
Cyclooxygenase 
pathway 
2 5.57E-03 
Regulation of response 
to stress 
7 4.51E-02 Cellular respiration 3 2.06E-02 
Inflammatory response 6 4.51E-02 Electron transport chain 3 2.09E-02 
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Some repetitive GO enriched terms can be seen among the different gene sets 
most notably: response to drug, response to stress, cellular respiration and electron 
transport chain. Moreover, unique GO enriched terms have been found. For example, in G6 
(H SF) regulation of programmed cell death, G8 (H SF SB) regulation of tumor necrosis factor 
production. And inflammatory response in the common genes. 
3.5 Pathway analysis  
Next, pathway analysis was explored only in regards to G6 (H SF) as it is the 
focus of this study. Pathway analysis were performed using ingenuity pathway analysis 
(IPA) software. For more stringent analysis, FDR threshold was changed to 0.01 
instead of 0.05, leaving total of 529 DEGs where 308 genes were up regulated and 221 
genes were down regulated. The most significant canonical pathways are presented in 
(Table 6).  Other canonical pathway of interest presented were oxidative 
phosphorylation and unfolded protein response.  
 
Table 6: List of top significant canonical pathway associated with G6 (H SF) 
 
Pathway p value 
Overlap 
percentage 
Genes 
Superpathway of 
cholesterol biosynthesis 
5.13E-07 29.60% 
ACAT2, EBP, FDPS, HADHB, HMGCR, 
HMGCS2, MSM01, PMVK 
Superpathway of 
geranylgeranyl 
diphosphate biosynthesis 
1 (via mevalonate) 
1.94E-06 40% 
ACAT2, FDPS, HADHB, HMGCR, 
HMGCS2,  PMVK 
Mevalonate pathway I 1.16E-05 41.70% 
ACAT2, HADHB, HMGCR, HMGCS2,  
PMVK 
Sirtuin signaling pathway 1.97E-05 8.50% 
ACADL, APP, ATP5F1A, CDH1, CPT1A, 
CPT1B, EPAS1, GABARAPL2, GADD45A, 
HMGCS2, IDH2,PGK1, SDHC, SLC25A5, 
SLC2A1, TIMM17A, 
TOMM40L,UQCRFS1, XPC 
Mitochondrial 
dysfunction 
3.32E-05 10.80% 
APP, ATP5F1A, ATP5MC3, ATP5MG, 
COX5A, CPT1A,CPT1B, HSD17B10, 
PINK1, PRDX3,SDHC, UQCRC1, 
UQCRFS1 
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 Furthermore, IPA offers toxicity functions linked to the DEGs provided and 
manually curated IPA knowledge base supporting clinical pathology endpoints. 
Among them “Hepatotoxicity” showed five top enriched toxicity functions which were 
liver steatosis, HCC, liver hyperplasia / hyperproliferation, liver cholestasis and liver 
damage. Focusing on our target HCC, IPA predicted an inhibition of HCC with p value 
of 8.27E-05 and total of 45 genes effecting HCC (Fig. 6). One of these 45 genes, 
HMGCR found to be inconsistent with the aim of this analysis while ACOX1 and 
CTNNB1 have a direct inhibition relationship. Leaving the rest of 42 genes with 
unpredicted effect. These 45 genes were reinvestigated in both hierarchical cluster 
analysis as it displayed the 45 gene expression profiles among the other experimental 
groups (Fig. 7) and BiNGO for GO enrichment analysis shown in (Table 7). 
 
Figure 6: Inhibition of HCC in G6 (H SF) 
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Table 7: GO enrichment analysis of the 45 genes involved in HCC inhibition 
Term name 
Genes 
number 
FDR Term name 
Genes 
number 
FDR 
Up regulated genes Down regulated genes 
Negative regulation of 
cell development 
2 4.77E-02 
Negative regulation of 
apoptosis 
3 2.95E-02 
Regulation of wound 
healing 
2 2.99E-02 
Negative regulation of 
programmed cell death 
3 2.95E-02 
Regulation of response 
to stress 
4 2.99E-02 Cell proliferation 2 4.98E-02 
Figure 7: Heatmap of the 45 genes involved in HCC inhibition. Hierarchical cluster 
analysis represents the mean of the triplicate for each group. Raw were centered and 
unit variance scaling was applied. Groups were clustered by maximum distance and 
complete linkage. Expression levels are coloured red for high expression and grey for 
low expression. 
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To further pinpoint genes associated with relevance biological functions to the 
HCC, these 45 genes were re-analyzed through IPA. Within the different functions 
provided, two functions standout from the rest which were incidence of malignant 
tumor and angiogenesis of tumor, both of which were decreased with p value of 7.49E-
06 and 1.10E-05, respectively. Total of 8 genes involved even though one of these 
genes, KDR showed inconsistency while three genes IQGAP1, KRAS and BRAF 
showed unpredicted effect (Fig. 8). 
 
3.6 String network analysis 
 String  network analysis provides an insight over the diverse interactions 
among the expressed proteins of interest. Theses interactions included the following: 
databases, experiments, gene neighborhood, gene fusion, gene co-occurrence, co-
expression, text-mining and protein homology. The higher the number of association 
dedicated to a certain node or hub, the higher the importance it projects. Hence, the 45 
genes involved in HCC inhibition and the 8 genes involved in incidence of malignant 
tumor and angiogenesis of tumor were examined for string network analysis (Fig. 9) 
and (Fig. 10) respectively. 
Figure 8: Incidence of malignant tumor and angiogenesis decline in G6 (H SF) 
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Figure 9: Network analysis of 45 proteins involved in HCC inhibition. The edges 
represents different protein-protein interaction colour coded; blue- curated databases, 
pink-experimentally determined, yellow- textmining, black- coexpression. 
Disconnected node were hidden. 
Figure 10: Network analysis of 8 proteins of interest. The edges represents different 
protein-protein interaction colour coded; blue- curated databases, pink-experimentally 
determined, yellow- textmining, black- coexpression. 
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3.7 qPCR quantification and validation  
Finally, a validation through qPCR is needed for the accuracy and 
reproducibility of gene expression results produced by RNA sequencing data. Five 
random DEGs were chosen from G6 (H SF) which were BTG1, PAWR, BMP4, 
DNAJB9 and CIDEA. The transcript level of these 5 genes were differently expressed 
and showed the same overall expression pattern (Fig. 11).   
At first both GAPDH and ACTB were chosen as reference genes however, both 
were up regulated, GAPDH was up regulated by 3.9 folds change while ACTB was up 
regulated by 7 fold change. Eventually, 18s rRNA was tested and shown a consistent 
expression hence was chosen as reference gene for qPCR data normalization. 
 
 
Figure 11: qPCR validation of five DEGs normalized against 18s rRNA 
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Chapter 4: Discussion 
 
 With the ongoing search for an effective anti-cancer drug to tame down HCC 
aggressiveness and prolong its associated survival comes the need to characterize and 
define the underlying mechanisms of action. For once, the anti-cancer activity of 
saffron constituent, safranal, is widely known, yet, the precise mechanism still not fully 
understood. Identification of specific genes that mediate an inhibitory reaction toward 
HCC will improve the available conventional therapies and might introduce safranal 
as a novel natural-based chemotherapeutic agent. 
In this study, a transcriptomic approach was used to assess safaranl’s 
therapeutic effect in DEN-induced HCC in vivo model. Two methodologies of 
dimension reduction, hierarchical cluster analysis and PCA were used to obtain an 
overall view on RNA sequencing data. G5 (H) have shown the expected change in 
gene expression profile and major variance compared to the other groups. Excitingly, 
G6 (H SF) have shown similar gene expression profile to control group G1 (C W) 
resulting in similar clustering. Additionally, G6 (H SF) showed smaller variance when 
compared to other control groups (G3 (C SB) and G4 (C SF SB)).   
Several studies invoke the cellular response of sorafenib that not only involve 
receptor tyrosine kinase (RTKs) signaling but extend it to mitochondrial quality 
control pathways that collectively lead to cancer suppression (Will et al., 2008; Coriat 
et al., 2012; Zhang et al., 2017). Sorafenib can induce the production of mitochondrial 
reactive oxygen species (mROS), although ROS are essential for cancer prosperity yet 
elevated level of extended ROS production can introduce cellular damage to the point 
where cell death becomes inevitable. Quite conveniently, cancer cells are extremely 
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sensitive to ROS induced by drugs (Chiou et al., 2009). In the present study, biological 
processes such as response to drug, response to stress, regulation of response to stress, 
response to oxidative stress, cellular respiration and electron transport chain have been 
consistently identified upon GO enrichment analysis on DEGs among the three 
experimental group G6 (H SF), G7 (H SB), G8 (H SF SB) and the common genes 
between them. This implies the fact that both safranal and sorafenib anti-cancer 
activities modulate mitochondrial quality control pathways. 
As the focus of this study is G6 (H SF), pathway analysis was mapped to DEGs 
of G6 (H SF). Top three canonical pathways were interconnected metabolomic 
pathways including superpathway of cholesterol biosynthesis, superpathway of 
geranylgeranyl diphosphate biosynthesis I and mevalonate pathway I. Evidence to link 
between cancer and metabolomic pathways had emerged and now metabolomics 
alteration  is considered among the hallmarks of cancer (Hanahan and Weinberg, 2011; 
Pavlova and Thompson, 2016). The constant need of cancer to grow and proliferate 
require an altered metabolic pathways that can meet its demands (Muñoz-Pinedo et al., 
2012). Some even raise the question if cancer after all is another metablomic disease 
(Coller, 2014). Intriguingly, cancer metabolism can be viewed as the classic response 
of drug resistance (Rahman and Hasan, 2015).  
Revisiting the top up regulated DEGs of G6 (H SF), CYP2B1 and CYP2B2 
were found, both of which come from cytochromes P450 (P450s) family.  P450s 
enzymes catalyze the metabolism of either endogenous substrates like steroids, fatty 
acids, and fat soluble vitamins or exogenous substrates like drugs and pesticides 
(Harleton, 2004). Enzymes from CYP2B family are involved in drug metabolism and 
xenobiotics (Schoedel and Tyndale, 2003). Hence, the action of metabolism of an anti-
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cancer drug by P450s enzymes may deactivate the cytotoxic activities of that drug. On 
the other hand, several prodrugs can be activated by P450s enzymes where prodrugs 
are needed to be metabolized first before exhibiting the active cytotoxic form 
(McFadyen et al., 2004). The evident overexpression of CYP2B1 and CYP2B2 may 
increase the breakdown of safranal and hence its secretion. Therefore, the optimal 
effects of safranal might not be seen due to loss of maintaining the proper level of the 
drug within the body. This might serve as a mechanism for drug tolerance. It is worth 
mentioning that even popular therapeutic agents are subjected to such response. For 
instance, paclitaxel used for ovarian, breast and non-small cell lung cancer is 
metabolized by CYP2C8 and CYP3A into deactivated form. Doxorubicin used for 
sarcoma, breast and ovarian cancer is metabolized by CYP3A4 into deactivated form. 
Cyclophosphamide used for sarcoma, breast and ovarian cancer is metabolized by 
CYP2B6 and CYP3A4 into activated form reflecting on the fact that 
cyclophosphamide is prodrug. (Kivisto et al., 1995). And since the prediction behind 
P450s enzymes metabolic pathway either drug activation or deactivation is not clear 
as it might increase the intrinsic pharmacodynamics activity of the drug or just simply 
deactivate the drug and facilitate its clearance from the body (Furge and Guengerich, 
2006). It is also conceivable that safranal’s metabolite/s, rather than its intact version, 
is the major contributor to the drug’s potent anti-cancer effect.  
Sirtuin signaling pathway was the fourth canonical pathway displayed. Cellular 
redox changes occurring due to oxidative, metabolic or genotoxic stress are detected 
and an adequate response is directed by sirtuin proteins. For instance, SIRT1, stress 
sensor, in stress condition it implement cell survival and drive the cell in cytoprotective 
manner but in extreme stress condition it leads the cell to apoptosis (Raynes et al., 
2013). Evidence have compiled over the dual functionality of sirtuin when it comes to 
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carcinogenesis (Bosch-Presegue and Vaquero, 2011; O'Callaghan and Vassilopoulos, 
2017). Although none of the sirtuin proteins family have been significantly detected 
in sirtuin signaling pathway, 9 out of 19 genes found in sirtuin signaling pathway were 
involved in cell death of tumor cells based on IPA ingenuity knowledge base.  
Mitochondrial dysfunction was the fifth canonical pathway observed. 
Mitochondrial dysfunction is greatly associated with cancer development and cancer 
metastatic potential (Chen, 2012; Hsu et al. 2016). However, contradicting data often 
resurface. To illustrate, various alterations in cellular redox state, respiratory chain 
complexes and mitochondrial functional parameters, induced oxidative stress and ROS 
production are all consequences of doxorubicin treatment that triggers mitochondria-
mediated apoptosis (Kuznetsov et al., 2011). Similar scenario may describe safranal 
anti-cancer activity. In fact, safranal correlates impeccably with the previous GO 
enrichment analysis. 6 out of 13 genes found in mitochondrial dysfunction were 
involved in cell death of tumor cells based on IPA ingenuity knowledge base.  Not to 
mention, oxidative phosphorylation was found within the canonical pathways 
indicating ROS production. 
Unfolding protein response is another appealing canonical pathway existed in 
pathway analysis. With the up regulation of DNAJB9, EDEM1 and PDIA6 all of which 
indicate endoplasmic reticulum (ER) stress (Shen et al., 2002; Olivari and Molinari, 
2007; Vekich et al., 2012). It has been reported that, if ER stress prolong and remain 
unresolved this might trigger autophagy and eventually leading to cell death (Luo and 
Lee, 2012). 
Primarily, 45 genes were found to be involved in HCC inhibition however, 
most of their involvements were labelled as unpredicted effect. Therefore, in the 
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interest of more conclusive findings, theses 45 genes were re-analysed. In comparison 
to other experimental groups, gene expression pattern showed a clear difference in the 
expression of these 45 genes implying the specificity of these genes to G6 (H SF). In 
addition to that, GO term enrichment revealed important biological processes 
empathizing on the decline in cell development, regulation of wound healing, decrease 
in cell proliferation and the negative regulation of both apoptosis and programmed cell 
death was declined.  
 The re-analysis of these 45 genes reinforced the inhibition of two functions of 
interest; incidence of malignant tumor and angiogenesis. Genes involved in the 
decrease of incidence of malignant tumor were ACOX1, CTNNB1 and CDH1 whereas 
genes involved in the decrease of angiogenesis of tumor were BRAF, CDH1 and 
SERPINC1. The rest of IQGAP1, KARS and BRAF shared unpredicted effect while 
KDR showed inconsistent relationship.   
Acyl-CoA oxidase 1 (ACOX1), is a rate-limiting enzyme of the peroxisomal 
fatty acid β-oxidation pathway of very long chain fatty acids (VLCFAs) (Vluggens et 
al., 2010). It has been established that deficient ACOX1 resulted in accumulation of 
VLCFAs and led to growth retardation, microvesicular steatohepatitis, apoptosis, liver 
regeneration, oxidative stress and ultimately HCC development (Huang et al., 2011).  
Catenin beta 1 (CTNNB1) is a cell surface cadherin protein complex subunit 
utilized as intracellular signal transducer in WNT signaling pathway; dysregulation in 
its activity has been strongly related to HCC progression (Monga, 2015). 
Unexpectedly, CTNNB1 has recently been introduced as tumor suppressive where KO 
mice experienced an intense HCC development after DEN treatment (Zhang et al., 
2010) while another study documented the same results after DEN and phenobarbital 
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treatment (Rignall et al., 2010). E-cadherin (CDH1) is transmembrane glycoprotein 
within the cadherins family essential for cell-cell adhesion in calcium dependent 
manner. Vital E-cadherin is a calcium-dependent cell-cell adhesion molecule playing 
a crucial in epithelial architecture establishment and cell polarity and differentiation 
maintenance (Liu and Chu, 2014). CDH1 has been recognized as tumor suppressor in 
number of cancers including lobular breast cancer, diffuse gastric carcinoma, ovarian 
cancer and colorectal carcinoma (Schrader et al., 2007; Kim et al., 2016; Wang et al., 
2016). CDH1 role in HCC was inconclusive and was thought early on to promote HCC 
growth (Wei, 2002). However, more recent accumulated evidence confirmed CDH1 
role in suppressing liver carcinogenesis (Nakagawa et al., 2014; Schneider et al., 2014; 
Zhu et al., 2017). CDH1 is also interestingly involved in binding and regulating 
CTNNB1 thus mediating growth suppression (Gottardi et al., 2001).  
Serpin family C member 1 (SERPINC1) is type of serine proteinase inhibitors 
also known as antithrombin, it prevents coagulation factors IX and X (Heit et al., 
2013). Its deficiency is associated with several diseases including liver cirrhosis, liver 
cancer, nephropathy and disseminated intravascular coagulation (DIC) (Lu et al., 
2017). SERPINC1 was described to effectively inhibit tumor angiogenesis in a mouse 
fibrosarcoma model (Larsson et al., 2000). However, its exact role in HCC is not well 
explored.  
Mitogen-activated protein kinase (MAPK) pathway consist of series of 
serine/threonine kinases which convey intracellular signals from extracellular 
molecules such as growth factors, differentiation factors, hormones and tumor-
promoting substance for cell proliferation, differentiation and survival purposes. 
Mainly, RAS, RAF, MEK and ERK are the key protein kinases in this pathway (Yang 
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and Liu, 2017). It has been found that 30% of cancers bar an activated RAS/RAF/MEK 
signaling cascade (Zhang et al., 2011). Thereby, a collective preclinical and clinical 
evidence compiled on irregular activation of Ras/Raf/MEK/ERK signaling pathway in 
HCC (Yang and Liu, 2017). Notably, blocking or inhibiting Ras/Raf/MEK/ERK 
signaling pathway has exhibited several anti-cancer activities (Li et al., 2016).  In the 
present study, KRAS, a member of RAS family and BRAF, a member of RAF family, 
were significantly down regulated upon safranal treatment and were associated with 
decrease of angiogenesis and tumor incidence.   
Finally and through string network analysis, regulatory hubs were identified 
based on the number of connections to other components in the same network. First 
network analysis of 45 genes involved in HCC inhibition, KRAS and CTNNB1 were 
recognized as regulatory hubs and similar outcome is drawn from the network analysis 
of 8 genes of interest. In addition to IQGAP1 which is strongly associated to HCC 
progression and can be used as HCC biomarker (Xia et al., 2014).  
Taken together, this study has assessed safranal’s anti-cancer properties on 
DEN induced HCC model through a transcriptomic analysis. Such analysis 
demonstrated a unique gene expression profile of safranal treated group and 
investigated associated biological processes and correlated canonical pathways in such 
a therapeutically treated animals. Current study, revealed key genes associated with 
HCC inhibition and explored further to attain their value as therapeutic candidates 
upon safranal treatment. 
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Chapter 5: Conclusion 
 
In conclusion, transcriptomic analysis herein clearly indicated the therapeutic 
effects of safranal against HCC in vivo model. Although signs of drug tolerance    was 
shown still that did not devalue its substantial anti-cancer effects. This study 
demonstrated safranal’s involvement in mitochondrial dysfunction, induced oxidative 
stress and increased ROS production and ultimately leading to cell death. Moreover, 
safranal caused disruption of the HCC activated MAPK pathway or 
Ras/Raf/MEK/ERK signaling pathway which in turns effects cell proliferation, 
differentiation and survival.  
Transcriptomic analysis using RNA sequence provides huge data to process 
yet it only offers one side of the story. The assumption that RNA transcripts 
corresponds perfectly to the expression of proteins generated is not always true. That 
is largely due to post-translational modifications. Hence, a proteomic study should 
follow up to deliver further insights into protein expression and interaction.  
Given the growing realization on the fact that single anti-cancer agent may not 
be as successful combating cancer, combination therapy seems to hold captivating 
qualities evading drug resistance and expansion of drug synergy effects. Further 
studies are currently underway to investigate the synergistic properties of safranal and 
sorafenib.  
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